Table 3 Multivariable analysis for progression-free and overall survival (<40 and ≥40 years)^a

Gender (reference; female)

Female vs Male

HR 0.41 (95% CI 0.13–1.33, P = 0.14)

HR 1.02 (95% CI 0.88–1.18, P = 0.81)

HR 1.11 (95% CI 0.38–3.20, P = 0.85)

HR 1.14 (95% CI 0.97–1.32, P = 0.10)

ECOG performance status (reference; 0)

0 vs 1

HR 4.94 (95% CI 1.13–21.52)

HR 1.05 (95% CI 0.89–1.23)

HR 3.59 (95% CI 0.79–16.37)

HR 1.02 (95% CI 0.86–1.20)

0 vs 2

HR 15.89 (95% CI 2.19–115.33)

[P = 0.01]

HR 1.39 (95% CI 1.04–1.85)

[P = 0.10]

HR 113.11 (95% CI 7.99–1600.53)

[P = 0.001]

HR 1.87 (95% CI 1.40–2.50)

[P = 0.0002]

Disease stage (reference; locally advanced)

Locally advanced vs Metastatic

HR 3.17 (95% CI 0.73–13.77, P = 0.12)

HR 1.38 (95% CI 1.17–1.64, P < 0.001)

HR 4.91 (95% CI 0.77–31.07, P = 0.09)

HR 1.40 (95% CI 1.18–1.68, P < 0.001)